Navigation Links
Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF)

currently marketed therapies in the form of significantly reduced bleeding complications. Ablynx has demonstrated a large therapeutic window for ALX-0081 based on the high efficacy and low bleeding demonstrated in primate studies, indicating a highly attractive drug profile.

Contacts:

At Ablynx:
Dr. Edwin Moses
Chairman and CEO
t : +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t : +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com


Visit our website: http://www.ablynx.com


The announcement distributed by Hugin directnews.
The issuer is solely responsible for the content of this announcement.

For address modifications please inform:

Tel.: 0049 (0) 341-2 24 56-30 or info@directnews.de
press kit: http://www.directnewsroom.de


'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/26/2008)...RT WORTH, Texas, Aug. 26 /- Healthpoi...l trial to evaluate the effectiveness of a,widely ...taneous wounds and,resulting scars. The pilot stud...e reduced incidence of hypertrophic scars and bene...ase SANTYL(R) Ointment.(1,2), "Given the findings...
(Date:8/25/2008)... Discovers Stem Cells Found in Menstrual Blood May...cts for Time-Pressed Women, OLDSMAR, Fla., Aug. 2.... Yet most women would agree that there never seem... a woman spends on doing something just,for hersel...sts in others.,This reality has led many women in ...
(Date:8/25/2008)...t Line CLL, NHL and CLL Retreatment and Japanese D...Planned, COPENHAGEN, Denmark, August 25 /PRNewswi...in four studies of ofatumumab in chronic lymphocyt.../S (OMX: GEN) announced today plans to begin four ...mia (CLL) and follicular,non-Hodgkin,s lymphoma (N...
(Date:8/21/2008)...NHATTAN, Kan., Aug. 21 /PRNewswire-USNewswire/ -- ...E. coli O157:H7 expert T.G. Nagaraja has,been tapp...both the,connection between feeding distillers, gr...ategies to reduce the presence of the naturally oc...eceived a $939,220 National Research Initiative in...
Breaking Medicine Technology:Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers' Grains 2Dr Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 114 1Dr Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 114 2Dr Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 114 3UK junior doctors gaining less experience of common procedures 115 1UK junior doctors gaining less experience of common procedures 115 2Ancient organisms discovered in Canadian gold mine 110 1Ancient organisms discovered in Canadian gold mine 110 2Survey reveals disparities in skin cancer knowledge protection among high school students 110 1Survey reveals disparities in skin cancer knowledge protection among high school students 110 2Survey reveals disparities in skin cancer knowledge protection among high school students 110 3
...a,clinical stage nanomedicine company focused on t...ional, tumor-targeted therapies has,been selected ...Society of Clinical Oncology Annual Meeting in Chi...ake place from 8:00 am to 12,noon on June 3. Dr. L...e poster abstract entitled "Preliminary Results of...
...from a large,randomized clinical trial for patien... typically found in bone marrow, has,shown that th...Decadron ®), in combination with lenalidomide ...val when compared to a treatment,regimen with lena...one. The clinical trial was sponsored by the Natio...
Other Medicine Technology:CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 2Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...common and deadly cancer worldwide. About 1.4 mill...out of which // 85% will die before 2010. Habit of... it is fastly increasing in low and middle income ...r occurrence is smoking. Globally smoking related ...
... or more pounds above ideal body weight. Obesity i...in developed countries. According to a recent rep...ently about 31 percent. In 1980 it was 23% and 15 ...ses problems with heart but also many other diseas...
...udy researchers say the drug orlistat (Xenical) co...ithout // major side effects in overweight teens. ...estines to absorb fat by up to 30 percent. However...istat passes through the body without being digest...
...to the fact that uncomplicated twin pregnancies ma...e. Researchers of Imperial College London report t...es have an increased risk from intrauterine deaths...egnancy, the twin fetuses share the same placenta ...
Other Medicine News:Health News:Aggressive Tobacco taxation policy can reduce cigarette smoking, 2
4 mm wide tip.
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end.
2.5 mm x 4 mm opening. Hexagonal handle.
Double-ended. Sharp and blunt 6.5 mm tips. Designated most popular model or size.
Medicine Products: